$3.2 Billion is the total value of EcoR1 Capital, LLC's 87 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SRPT | New | SAREPTA THERAPEUTICS INC | $161,680,000 | – | 2,069,634 | +100.0% | 5.06% | – |
ZLAB | New | ZAI LAB LTDadr | $97,777,000 | – | 2,223,212 | +100.0% | 3.06% | – |
RETA | New | REATA PHARMACEUTICALS INCcl a | $64,721,000 | – | 1,975,611 | +100.0% | 2.02% | – |
CERE | New | CEREVEL THERAPEUTICS HLDNG I | $57,636,000 | – | 1,646,260 | +100.0% | 1.80% | – |
MRTX | New | MIRATI THERAPEUTICS INC | $41,161,000 | – | 500,622 | +100.0% | 1.29% | – |
ARGX | New | ARGENX SEsponsored adr | $39,414,000 | – | 125,000 | +100.0% | 1.23% | – |
RVMD | New | REVOLUTION MEDICINES INC | $32,502,000 | – | 1,274,097 | +100.0% | 1.02% | – |
BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $24,022,000 | – | 547,453 | +100.0% | 0.75% | – |
EXEL | New | EXELIXIS INC | $21,567,000 | – | 951,333 | +100.0% | 0.68% | – |
GERN | New | GERON CORP | $19,429,000 | – | 14,285,714 | +100.0% | 0.61% | – |
SWTX | New | SPRINGWORKS THERAPEUTICS INC | $18,393,000 | – | 325,881 | +100.0% | 0.58% | – |
ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $17,247,000 | – | 895,503 | +100.0% | 0.54% | – |
SURF | New | SURFACE ONCOLOGY INC | $13,680,000 | – | 4,653,000 | +100.0% | 0.43% | – |
HOOK | New | HOOKIPA PHARMA INC | $11,400,000 | – | 5,000,000 | +100.0% | 0.36% | – |
KDNY | New | CHINOOK THERAPEUTICS INC | $11,288,000 | – | 690,000 | +100.0% | 0.35% | – |
NGM | New | NGM BIOPHARMACEUTICALS INC | $8,252,000 | – | 541,108 | +100.0% | 0.26% | – |
IGMS | New | IGM BIOSCIENCES INC | $7,981,000 | – | 298,597 | +100.0% | 0.25% | – |
ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $5,317,000 | – | 115,236 | +100.0% | 0.17% | – |
GRCL | New | GRACELL BIOTECHNOLOGIES INCsponsored ads | $3,634,000 | – | 1,559,710 | +100.0% | 0.11% | – |
MRSN | New | MERSANA THERAPEUTICS INC | $1,303,000 | – | 326,578 | +100.0% | 0.04% | – |
BCEL | New | ATRECA INC | $1,137,000 | – | 358,780 | +100.0% | 0.04% | – |
EUCRW | New | EUCRATES BIOMEDICAL ACQU CORcall | $656,000 | – | 66,666 | +100.0% | 0.02% | – |
RDUS | New | RADIUS HEALTH INC | $309,000 | – | 35,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
XENCOR ORD | 25 | Q3 2023 | 12.6% |
ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
PROTHENA ORD | 20 | Q3 2023 | 28.0% |
IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-05-03 |
SC 13G/A | 2024-04-08 |
3 | 2024-03-26 |
SC 13G/A | 2024-03-26 |
SC 13G | 2024-03-11 |
SC 13D | 2024-02-22 |
SC 13G | 2024-02-16 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.